IP Library › Granted Patent US 11,234,751
Granted Patent B2
US 11,234,751 · App. 15/884,604 · Granted Feb 1, 2022

Characterizing ablation lesions using optical coherence tomography (OCT)

Inventors: Andrew M. Rollins (Cleveland Heights, OH); Christine P. Fleming (Bronx, NY)
Assignee: CASE WESTERN RESERVE UNIVERSITY
A61B18/12A61B5/0066A61B5/6852A61B18/1492A61B18/02A61B18/20A61B2017/00243A61B2018/00351A61B2018/00702A61B2090/3735
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,234,751
App. No.
15/884,604
Filed
Jan 31, 2018
Granted
Feb 1, 2022
Kind
B2
Art Unit
3792
USPC
606/15
Abstract

Systems, methods, and other embodiments associated with characterizing Radio Frequency Ablation (RFA) lesions using Optical Coherence Tomography (OCT) are described. One example method includes acquiring an OCT signal from a Region Of Interest (ROI) in an ablated material. The example method may also include determining whether a lesion was formed by the ablation by analyzing optical properties of the ROI as recorded in the OCT signal.

Claims (20)

1. A system comprising:

an ablation device to ablate a region of interest (ROI) in a material;

an optical coherence tomography (OCT) device to acquire an OCT signal from the ROI; and

a computing device coupled to the OCT device to analyze optical properties of the ROI based on the OCT signal to guide ablation of the ROI based on the optical properties, wherein the computing device analyzes the optical properties to determine a development stage of a lesion formed by the ablation, and the computing device controls the ablation device to stop ablating the ROI in response to determining that the development stage of the lesion is a clinically relevant lesion stage or a borderline overtreatment lesion stage.

2. The system of claim 1 , wherein the OCT device further comprises a lens, an optical assembly and a fiber optical cable, at least one of which is adapted to rotate to implement scanning across the surface of the ROI, the OCT signals being generated responsive to the scanning.

3. The system of claim 1 , wherein the ablation device and the OCT device are enclosed within an ablation catheter.

4. The system of claim 1 , wherein the OCT signal is acquired continuously or intermittently during the ablation procedure.

5. The system of claim 1 , wherein the OCT signal is acquired at time points when the ablation is paused during the ablation procedure.

6. The system of claim 1 , wherein the optical properties to determine the development stage of the lesion comprise birefringence and backscattering.

7. The system of claim 1 , wherein the computing device applies signal processing to the OCT signal to determine the optical properties of the ROI, the computing device analyzing the optical properties of the ROI to determine at least one of a size and a depth of a lesion formed at the ROI by the ablation.

8. The system of claim 1 , wherein the computing device applies signal processing to the OCT signal to determine at least one of tissue heterogeneity and anisotropy of the ROI, and wherein the computing device determines the development stage of the lesion based on the at least one of tissue heterogeneity and anisotropy of the ROI.

9. The system of claim 1 , wherein the optical properties comprise at least one of birefringence, absorption, light attenuation rate, backscattering and mean intensity.

10. A system comprising:

an ablation device to ablate a region of interest (ROI) in a material;

an optical coherence tomography (OCT) device to acquire an OCT signal from the ROI; and

a computing device coupled to the OCT device to analyze optical properties of the ROI based on the OCT signal to guide ablation of the ROI based on the optical properties, wherein the computing device analyzes the optical properties to determine a development stage of a lesion formed by the ablation, the computing device provides a control signal to the ablation device to stop ablating the ROI in response to determining that the development stage of the lesion is a clinically relevant lesion stage or a borderline overtreatment lesion stage,

wherein the computing device determines a tissue architecture of the material based on the optical properties of the ROI as recorded in the OCT signal.

11. The system of claim 10 , wherein the tissue architecture comprises at least one of fiber orientation, epicardial fat and an intracardiac structure.

12. The system of claim 11 , wherein the intracardiac structure comprises at least one of a coronary vessel, an atrio-ventricular node and a sino-atrial node.

13. The system of claim 10 , wherein the optical properties of the ROI comprise birefringence and backscattering.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2018
From: ROLLINS, ANDREW M.; FLEMING, CHRISTINE P.
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 046367/0044 →
Continuity (4)
Continuation 14674539 · Mar 31, 2015
Continuation 12844944 · Jul 28, 2010
Provisional Application 61230281 · Jul 31, 2009
Related Publication 20180153608A1 · Jun 7, 2018
Cited By (1)
US 12,733,792